EXOSC10 and calcinosis: In addition to overlap disease anti-PmScl were also associated with the development of calcinosis (OR 3.31 (1.29–8.52), p = 0.013) and lipoatrophy (OR 3.08 (1.09–8.77), p = 0.035).